Emergent Biosolutions, Inc.

Day range

$6.14 – $6.40

Open

$6.28

Prev close

$6.23

Volume

485.43K

Market cap

$319.43M

Shares out

51.27M

P/E

—

P/S

0.41

P/B

0.94

P/FCF

3.72

ROE

-51.8%

ROA

-15.8%

Debt/Equity

1.70

Div yield

0.00%

As of Oct 23, 2026

• Cfo appointmentOct 16, 2026

  The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company's Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027. Prior to his retirement date, Mr. Lindahl will assist with the transition of his responsibilities.

• Investor presentationSep 14, 2026

  On September 14, 2026, Joseph C. Papa, president and chief executive officer of Emergent BioSolutions Inc., will present at the H.C. Wainwright 28th Annual Global Investment Conference. Mr. Papa will present the slides furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Significant contract awardSep 1, 2026

  On August 18, 2026, Emergent BioSolutions Inc. received a contract modification ("Modification No. 21") of the BARDA AV7909 Contract from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) valued at $24 million.

• Restructuring planAug 5, 2026

  On August 5, 2026, the Company announced an organizational restructuring plan (the "Restructuring Plan") intended to strengthen its long-term financial position in response to changes in its business. These strategic actions will lead to a reduction of the Company's current workforce by approximately 93 employees across all areas of the Company and the elimination of approximately 21 positions that are currently vacant, as well as the closure of wet laboratories in Gaithersburg, Maryland... these actions are expected to result in annualized savings of approximately $40 million when fully implemented.

• Significant contract awardJun 29, 2026

  Emergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response ('ASPR'), exercising Option Year 7 for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government under Emergent's existing 10-year contract with ASPR. Modification No. 15 is valued at $52.7 million and requires Emergent to deliver doses of ACAM2000®, ancillaries as well as diluent replacement lots to the U.S. government in June 2026, and any remaining balance of diluent by December 2026.

• JNJJohnson & Johnson+0.94%

Days to cover

8.3

Short interest

9.29M

Avg volume

1.12M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
  neutralZacks Investment Research· Oct 6, 2026
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
  negativeGlobeNewswire Inc.· Sep 22, 2026
• Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider
  positiveGlobeNewswire Inc.· Sep 9, 2026
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
  negativeGlobeNewswire Inc.· Sep 8, 2026
• Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
  positiveGlobeNewswire Inc.· Feb 12, 2026